Member Info for RollingInIt

Keeptofacts

Perhaps it's worth following the suggestion in your name and the recent developments rather than mere conjecture based on your personal historical bitter experiences.

A major Japanese pharmaceutical, valued at least 15,000 to 30,000 + times that of VAL with £Billions at it's disposal and the expertise that is afforded by it's available cash, wishes to collaborate with VAL for it's drug for a reason, particularly after having conducted a thorough review of VAL

VAL's value at around £2 Million is a pittance and is ridiculously undervalued as a result and is worth many multiples on this collaboration alone.

Kbizt

Your summary is flawed throughout and a complete misrepresentation of the investment case laid out by Myles McNulty. An intentional misrepresentation in my view but any reader can decide for themselves.

Firsrly, he references $ 100's of Billions target market for AVCT's tests, not just $ 100 Billion.

This is as a result of the renowned US economist stating only yesterday on the BBC that $ 100 Billion will need to be spent on tests in the US alone.

That $ 100 Billion represents the 22 million tests a day that the economist stated is necessary to regain the US economy. 22 million tests a day equates to 8.3 billion tests a year, which dismisses your other claim that the $ 100 Billion is based on tests costing hundreds of $'s. Actually, it would equate to tests costing just over $ 12.

Additionally, the US population only represents 20% of the population in advanced economies, which is 1.5 billion, so $100 Billion spend in the US would translate to many hundreds of $ Billions globally.

You then state $25 Billion sales , MM didn't write that at all.
Then you write earnings from sales $ 5 Billion and then attempt to reduce it further by suggesting a 15 % royalty on your made up $ 5 Billion earnings.

MM wrote he anticipated a 10% royalty on all sales.

So, in your example of $ 25 Billion sales of the AVCT test, this would equate to $ 2.5 Billion to AVCT in royalties.

The distribution costs would be with Cytiva and the intellectual and commercial rights belong to AVCT.

You then state a 50% COS, or chance of success. MM didn't write that either, he wrote 90 - 95% COS.

Even so, if they were earning $ 2.5 Billion per annum ( and by the way, that same US economist stated the $100 Billion on tests would need to be spent for years, to stop the US economy from losing $ 6 Trillion per annum in revenue), a COS would be irrelevant and not diminish the market cap valuation, and the market cap would be multiples of their royalty earnings.

In short, the £200 million market cap does not represent the potential of having a good portion of a half a $ Trillion ++ global market.

In the same way, your purposefully naff summary does not represent the summary given by Myles McNulty.

JonesRichard

No, this isn't AVCT.

It's a clumsy affair, has to be sent off for results, and takes on average 24 hours.

AVCT's is on a lateral 'pregnancy test type' strip, doesn't have to be sent anywhere and takes 10 minutes for results.

________

Patients, sitting in their cars, cough a few times to bring up fluid from the lungs and then swab the inside of their cheeks and roofs of their mouths. They put the specimen in a vial, seal it up and drop it in a bin,

The company says the tests, analyzed nearby at KorvaLabs in San Dimas, are turned around in 24 hours on average

Hence the speculation here. :o)

They wanted a Uk solution.

RNS on the 9th of April, AGM statement.

5th Paragraph.

This part being of most interest:

The Directors are actively working with the Company's partners, and reaching out directly to the UK Government, to inform its decision making.

The ultimate aim is to be part of a technology solution to supress the spread of COVID-19 while allowing some form of normality to return to the economy and to everyday lives. "

Which would explain the reason behind a renewed interest in the stock.

"One such opportunity is to use the Company's location technology and considerable knowhow to assist the UK Government in understanding the effects of its policies, as well as to be part of any track and trace COVID-19 solution. The Directors are actively working with the Company's partners, and reaching out directly to the UK Government, to inform its decision making. The ultimate aim is to be part of a technology solution to supress the spread of COVID-19 while allowing some form of normality to return to the economy and to everyday lives. "

Morwen

Hate to break it to you like this, but nobody really gives a damn what you do with your money, or what I do with my money, or what anyone else does with their money.

That's where it should be ..... back to the IPO price, which would only be £7 Mill market cap.

400% rise from current 6p.

Lidl and Tesco.

'Demand for the company’s services has increased as public health restrictions on movement has led shoppers to turn to online delivery services to protect themselves from catching Covid-19, the deadly disease caused by virus. ....

.... Devan Hughes, Buymie’s chief executive and co-founder, said the company will, with the new funding, be able to increase revenues by 500 per cent by the end of the year on last year’s figure.
The company is turning over a seven-figure sum every month, he said

______

I think it's going to 'bag many times quickly' here too.

That's Akers' M.O.

More likely to have the same effect here that he's just had on AAA over the last month.

0.1 up to 1.65 and rising.

: o)

JCEP

Maybe they do have a President. :o)

Jocularity aside, the two medical bodies have already stated that their approach to COV19 is different to the norm and everything COV19 is being expedited, so we'll see if the recovery of patients and prevention of deaths takes precedence over usual practice, which I'm guessing it will.

No offence JCEP.

She won't know unless she's one of the decision makers involved in authorising the trial.

Normally, it would follow with a Phase 3 .... which in itself is a win .... because it informs us that Phase 2 has been a success .... but the current circumstance is anything but normal and everything COV19 is being fast tracked.

Peter

I can't see a Phase 3 being necessary given the urgency of preventing those infected being put on a ventilator, which is what early intervention with SNG's inhaled Interferon B aims to do, removing the need for ventilators.

I can see it just being rolled out or expanded in use.

Either way, it's a win because it tells us that it's having a positive effect.

Riddler

Yes, that's a good endorsement and he's looking to hold onto them by all accounts

Zebbo

If you're referring to the £2 short term forecast of Myles McNulty, his forecast for medium term is 'Multi Billion', which would dictate a share price of £10 +.

Worth noting that his forecasts can be conservative. He forecast NCYT at £2.50 and it doubled that.

Reported in the USA today:

______

On Tuesday, Cuomo said any decision to reopen would have “to be phased. It has to be balanced. It’s a public health strategy and an economic reactivation strategy.

“The key to me is testing. People have to know that they are safe and the testing actually works to make people feel safe, and we don’t have that capacity now … We have to develop that widespread testing capacity.”

_____

AVCT's tie up with GE Healthcare/Cytiva is well set to achieve the above and GE/Cytiva have a global reach and are responsible for 75% of all FDA approvals during 2019 for biological therapies.